Discovery and confirmation of protein action site AK1 of ginsenosides in brain based on DARTS technology.
10.19540/j.cnki.cjcmm.20211117.703
- Author:
Fei-Yan CHEN
1
;
Wei QIN
2
;
Rui-Mei LI
2
;
Yao CHENG
2
;
Zhu ZHU
2
;
Lin CHEN
2
;
Yu-Nan ZHAO
2
Author Information
1. School of Chinese Medicine & Integrated Chinese and Western Medicine, Nanjing University of Chinese Medicine Nanjing 210023, China.
2. School of Medicine & Holistic Integrative Medicine, Nanjing University of Chinese Medicine Nanjing 210023, China.
- Publication Type:Journal Article
- Keywords:
DARTS;
adenylate kinase;
ginsenosides;
protopanaxadiol;
targets
- MeSH:
Brain/metabolism*;
Chromatography, Liquid;
Ginsenosides;
Molecular Docking Simulation;
Technology
- From:
China Journal of Chinese Materia Medica
2022;47(5):1336-1342
- CountryChina
- Language:Chinese
-
Abstract:
This study aims to explore the targets of ginsenosides in brain based on drug affinity responsive target stability(DARTS) technology. Specifically, DARTS technology was combined with label-free liquid chromatography tandem mass spectrometry(LC-MS) to screen out the proteins in the brain that might interact with ginsenosides. Based on the screening results, adenylate kinase 1(AK1) was selected for further confirmation. First, the His-AK1 fusion protein was yielded successively through the construction of recombinant prokaryotic expression vector, expression of target protein, and purification of the fusion protein. Biolayer interferometry(BLI) was employed to detect the direct interaction of Rg_1, Re, Rb_1, Rd, Rh_2, F1, Rh_1, compound K(CK), 25-OH-PPD, protopanaxa-diol(PPD), and protopanaxatriol(PPT) with AK1, thereby screening the ginsenoside monomer or sapogenin that had strong direct interaction with the suspected target protein AK1. Then, the BLI was used to further determine the kinetic parameters for the binding of PPD(strongest interaction with AK1) to His-AK1 fusion protein. Finally, molecular docking technology was applied to analyze the binding properties between the two. With DARTS and LC-MS, multiple differential proteins were screened out, and AK1 was selected based on previous research for target verification. Fusion protein His-AK1 was obtained by prokaryotic expression, and the response(nm) of Re, Rg_1, Rd, Rb_1, Rh_1, Rh_2, F1, PPT, PPD, 25-OH-PPD, and CK with His-AK1 was respectively 0.003 1, 0.001 9, 0.042 8, 0.022 2, 0.013 4, 0.037 3, 0.013 9, 0.030 7, 0.140 2, 0.016 0, and 0.040 8. The K_(on), K_(off), and K_D values of PPD and His-AK1 were determined by the BLI as 1.22×10~2 mol~(-1)·L·s~(-1), 1.04×10~(-2) s~(-1), 8.52×10~(-5) mol·L~(-1). According to the molecular docking result, PPD bound to AK1 with the absolute value of the docking score of 3.438, and hydrogen bonds mainly formed between the two. Thus, AK1 is one of the protein action sites of ginsenosides in the brain. The direct interaction between ginsenoside metabolite PPD and AK1 is the strongest.
